HK1253355B - 含有馬西替坦的治療組合物 - Google Patents

含有馬西替坦的治療組合物

Info

Publication number
HK1253355B
HK1253355B HK18112650.6A HK18112650A HK1253355B HK 1253355 B HK1253355 B HK 1253355B HK 18112650 A HK18112650 A HK 18112650A HK 1253355 B HK1253355 B HK 1253355B
Authority
HK
Hong Kong
Prior art keywords
compositions containing
therapeutic compositions
containing macitentan
macitentan
therapeutic
Prior art date
Application number
HK18112650.6A
Other languages
English (en)
Other versions
HK1253355A1 (zh
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1253355(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of HK1253355A1 publication Critical patent/HK1253355A1/zh
Publication of HK1253355B publication Critical patent/HK1253355B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK18112650.6A 2008-08-13 2018-10-03 含有馬西替坦的治療組合物 HK1253355B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13

Publications (2)

Publication Number Publication Date
HK1253355A1 HK1253355A1 (zh) 2019-06-14
HK1253355B true HK1253355B (zh) 2020-06-19

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112650.6A HK1253355B (zh) 2008-08-13 2018-10-03 含有馬西替坦的治療組合物

Country Status (29)

Country Link
US (3) US8809334B2 (zh)
EP (2) EP3300729B1 (zh)
JP (3) JP5764061B2 (zh)
KR (1) KR101678699B1 (zh)
CN (1) CN102099026B (zh)
AR (1) AR073031A1 (zh)
AU (1) AU2009280843B2 (zh)
BR (1) BRPI0917661B8 (zh)
CA (1) CA2731370C (zh)
CY (2) CY1119826T1 (zh)
DK (2) DK3300729T3 (zh)
ES (2) ES2652590T3 (zh)
HK (1) HK1253355B (zh)
HR (2) HRP20171917T1 (zh)
HU (2) HUE036071T2 (zh)
IL (1) IL211143A0 (zh)
LT (2) LT3300729T (zh)
MA (1) MA32614B1 (zh)
MX (1) MX350011B (zh)
MY (1) MY178894A (zh)
NO (1) NO2315587T3 (zh)
NZ (1) NZ591601A (zh)
PL (2) PL2315587T3 (zh)
PT (2) PT2315587T (zh)
RU (1) RU2519161C2 (zh)
SI (2) SI3300729T1 (zh)
TW (1) TWI446911B (zh)
WO (1) WO2010018549A2 (zh)
ZA (1) ZA201101900B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
DK2246336T3 (da) 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
BRPI0917661B8 (pt) 2008-08-13 2021-05-25 Actelion Pharmaceuticals Ltd produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
BR112019012251A2 (pt) 2016-12-14 2019-11-05 Respira Therapeutics Inc métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares
WO2020056104A1 (en) * 2018-09-14 2020-03-19 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
SI3897646T1 (sl) * 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
NZ525614A (en) 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
AU2002229573A1 (en) * 2000-12-19 2002-07-01 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (zh) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
ES2320649T3 (es) 2002-12-02 2009-05-27 Actelion Pharmaceuticals Ltd. Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina.
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
PL2254570T3 (pl) 2008-02-20 2014-05-30 Actelion Pharmaceuticals Ltd Połączenie zawierające paklitaksel do leczenia raka jajnika
BRPI0917661B8 (pt) 2008-08-13 2021-05-25 Actelion Pharmaceuticals Ltd produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina

Also Published As

Publication number Publication date
JP2011530581A (ja) 2011-12-22
SI3300729T1 (sl) 2020-02-28
WO2010018549A3 (en) 2010-07-29
EP3300729B1 (en) 2019-10-09
US9173881B2 (en) 2015-11-03
AU2009280843B2 (en) 2015-03-05
HUE047767T2 (hu) 2020-05-28
CA2731370A1 (en) 2010-02-18
PL2315587T3 (pl) 2018-03-30
KR20110045006A (ko) 2011-05-03
WO2010018549A2 (en) 2010-02-18
DK2315587T3 (en) 2018-01-02
US20110136818A1 (en) 2011-06-09
US20140329824A1 (en) 2014-11-06
ES2652590T3 (es) 2018-02-05
HRP20171917T1 (hr) 2018-02-09
HK1253355A1 (zh) 2019-06-14
AR073031A1 (es) 2010-10-06
MY178894A (en) 2020-10-21
NO2315587T3 (zh) 2018-03-24
US8809334B2 (en) 2014-08-19
MX2011001625A (es) 2011-03-29
CY1119826T1 (el) 2018-06-27
US20160022678A1 (en) 2016-01-28
JP2015180683A (ja) 2015-10-15
CA2731370C (en) 2017-03-14
RU2011109084A (ru) 2012-09-20
ZA201101900B (en) 2012-08-29
BRPI0917661B8 (pt) 2021-05-25
AU2009280843A1 (en) 2010-02-18
MA32614B1 (fr) 2011-09-01
JP5764061B2 (ja) 2015-08-12
JP2015187148A (ja) 2015-10-29
EP3300729A1 (en) 2018-04-04
CN102099026B (zh) 2012-08-29
JP5956026B2 (ja) 2016-07-20
IL211143A0 (en) 2011-04-28
PL3300729T3 (pl) 2020-04-30
DK3300729T3 (da) 2020-01-20
NZ591601A (en) 2012-12-21
LT3300729T (lt) 2020-01-10
SI2315587T1 (en) 2018-04-30
HUE036071T2 (hu) 2018-06-28
LT2315587T (lt) 2018-01-10
JP5956025B2 (ja) 2016-07-20
TW201010985A (en) 2010-03-16
CY1122641T1 (el) 2021-03-12
PT3300729T (pt) 2020-01-20
EP2315587A2 (en) 2011-05-04
BRPI0917661B1 (pt) 2019-12-17
US9597331B2 (en) 2017-03-21
MX350011B (es) 2017-08-22
BRPI0917661A2 (pt) 2015-12-01
EP2315587B1 (en) 2017-10-25
CN102099026A (zh) 2011-06-15
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
PT2315587T (pt) 2018-01-31
TWI446911B (zh) 2014-08-01
ES2763176T3 (es) 2020-05-27
HRP20192204T1 (hr) 2020-03-06

Similar Documents

Publication Publication Date Title
HK1253355A1 (zh) 含有馬西替坦的治療組合物
ZA201200054B (en) Therapeutic compounds and compositions
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
IL228817A0 (en) Pharmaceutical compounds
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2323623T3 (pl) Kompozycje farmaceutyczne
EP2236149A4 (en) MEDICAL COMPOSITION
GB0808835D0 (en) Therapeutic compositions
IL208387A0 (en) Pharmaceutical composition
GB0819958D0 (en) Therapeutic compositions
ZA201006224B (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
GB2464200B (en) Pharmaceutical composition
GB0900786D0 (en) Therapeutic compositions
EP2490704A4 (en) THERAPEUTIC COMPOSITION
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
GB0819960D0 (en) Therapeutic composition
GB0710144D0 (en) Therapeutic compositions
IL210519A0 (en) Anti-phthiraptera treatment compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS